香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1518 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 茲提述新世紀醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 截至二零二二年十二月三十一日止年度的年度報告（於二零二三年四月二十七 日在聯交所網站(www.hkexnews.hk)刊發，「二零二二年度報告」）。除另有界定 外，本公告內所用詞彙與二零二二年度報告內所界定者具有相同涵義。 除二零二二年度報告所提供的資料外，董事會謹此向股東及本公司潛在投資 者提供更多詳情，內容有關僱員股份計劃。於二零二二年十二月三十一日，僱 員股份計劃項下可供授出的本公司股份總數仍為24,501,250股，相當於董事會 在二零二零年八月二十八日所批准及採納的5%計劃限額。於二零二二年十二 月三十一日，計劃限額保持不變，仍為5%。 承董事會命 新世紀醫療控股有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1518 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 及 有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易 茲提述新世紀醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 截至二零二二年十二月三十一日止年度的年度報告（於二零二三年四月二十七 日在聯交所網站(www.hkexnews.hk)刊發，「二零二二年度報告」）。除另有界定 外，本公告內所用詞彙與二零二二年度報告內所界定者具有相同涵義。 除二零二二年度報告所提供的資料外，董事會謹此向股東及本公司潛在投資 者提供更多詳情，內容有關(i)截至二零二二年十二月三十一日止年度的非流動 資產減值虧損；(ii)截至二零二二年十二月三十一日止年度的金融資產減值虧損； 及(iii)有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 1518 有關截至二零二二年十二月三十一日止年度的年度報告的補充公告 及 有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易 茲提述新世紀醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 截至二零二二年十二月三十一日止年度的年度報告（於二零二三年四月二十七 日在聯交所網站(www.hkexnews.hk)刊發，「二零二二年度報告」）。除另有界定 外，本公告內所用詞彙與二零二二年度報告內所界定者具有相同涵義。 除二零二二年度報告所提供的資料外，董事會謹此向股東及本公司潛在投資 者提供更多詳情，內容有關(i)截至二零二二年十二月三十一日止年度的非流動 資產減值虧損；(ii)截至二零二二年十二月三十一日止年度的金融資產減值虧損； 及(iii)有關向嘉華麗康提供財務資助的過往須予公佈交易及關連交易。 ...

Financial Performance - New Century Healthcare reported a total revenue of RMB 10.4 million for the year ended December 31, 2022, which is a slight decrease from the annual cap of RMB 10.5 million[31]. - The company reported a total comprehensive loss attributable to owners of RMB 101,461,000 for the year, compared to a loss of RMB 85,262,000 in 2021, indicating a worsening financial performance[163]. - The net loss for the year was RMB 291,573 thousand, compared to a net loss of RMB 85,262 thousand in 2021, indicating a significant increase in losses[186]. - Basic and diluted loss per share for the year was RMB 0.62, compared to RMB 0.21 in the previous year, showing a deterioration in earnings per share[186]. - The accumulated losses increased significantly from RMB 371,592 thousand in 2021 to RMB 669,326 thousand in 2022, representing an increase of approximately 80.2%[159]. - Total revenue for the year ended December 31, 2022, was RMB 636,459 thousand, a slight increase from RMB 632,565 thousand in 2021, representing a growth of approximately 0.6%[186]. Corporate Governance - The company aims to maintain a high standard of corporate governance to enhance transparency and accountability in its business strategies[41]. - The company has complied with all applicable code provisions of the Corporate Governance Code, except for the separation of the roles of Chairman and CEO[68]. - The board currently consists of 12 members, with 3 women, resulting in a female representation of 25%[86]. - The company has a board diversity policy that considers various factors including professional qualifications, industry experience, and gender[79]. - The company aims to enhance gender diversity on the board and will continue to increase the proportion of female members as suitable candidates are identified[86]. - The nomination committee will monitor the implementation of the board diversity policy and review the composition of the board at least annually[108]. Audit and Compliance - The company’s independent auditors provided an unqualified opinion on the disclosed continuing related transactions[27]. - The company has appointed PwC as its auditor for the year ending December 31, 2022, and will propose their reappointment at the upcoming annual general meeting[67]. - All independent non-executive directors have confirmed their independence in writing according to listing rules[72]. - The audit committee held three meetings in 2022 to review interim and annual financial performance and significant matters related to financial reporting[100]. Financial Position - The total assets decreased from RMB 1,270,896 thousand in 2021 to RMB 901,384 thousand in 2022, representing a decline of approximately 29.1%[159]. - The company's total equity decreased from RMB 684,238 thousand in 2021 to RMB 361,351 thousand in 2022, a decline of about 47.3%[159]. - The total liabilities decreased to RMB 540,033 thousand in 2022 from RMB 586,658 thousand in 2021, reflecting a reduction of about 7.9%[184]. - Non-current liabilities decreased from RMB 295,481 thousand in 2021 to RMB 206,221 thousand in 2022, a reduction of approximately 30.2%[184]. - The total equity and liabilities amounted to RMB 901,384 thousand in 2022, down from RMB 1,270,896 thousand in 2021, a decrease of approximately 29.1%[184]. Operational Highlights - The company continues to focus on pediatric and obstetric specialty services in China, along with hospital consulting and online medical services[189]. - The company has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee to oversee its affairs[50]. - The Remuneration Committee held one meeting in 2022 to review the company's remuneration policies and provide recommendations to the board[51]. - The Nomination Committee also held one meeting in 2022 to review the structure and independence of the board[52]. Cash Flow and Investments - Operating cash flow for the year ended December 31, 2022, was RMB 106,550,000, an increase from RMB 62,700,000 in 2021, representing a growth of 69.9%[165]. - Net cash generated from operating activities was RMB 76,280,000, significantly up from RMB 22,255,000 in the previous year, indicating a substantial improvement in operational efficiency[165]. - The company incurred a net cash outflow from investing activities of RMB 23,068,000, compared to RMB 15,743,000 in the previous year, indicating increased investment activity[165]. Risk Management and Internal Controls - The company focuses on risk management and internal controls, emphasizing customer and employee safety, quality control, and general risk management[114]. - The company’s internal control processes are regularly reviewed and assessed for effectiveness, although they cannot guarantee the absolute prevention of significant errors or fraud[114]. - The company conducts annual impairment tests for goodwill and other intangible assets, adjusting for any identified impairments[122]. Asset Management - The company reported a goodwill impairment assessment as of December 31, 2022, indicating potential risks in asset valuation[143]. - The company utilized a sensitivity analysis to evaluate the impact of key assumptions on the recoverable amount of cash-generating units[145]. - The company’s management made significant judgments regarding expected credit loss estimates based on historical credit records and macroeconomic parameters[147].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部份內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 1518 截至二零二二年十二月三十一日止年度的年度業績公告 二零二二年度業績摘要 以下載列本集團截至二零二二年十二月三十一日止年度的主要業績摘要： 1. 我們於截至二零二二年十二月三十一日止年度錄得收益約人民幣636.5百萬元， 與二零二一年相比小幅增加0.6%。 2. 年內除所得稅前虧損增加至人民幣289.9百萬元，而去年為人民幣59.1百萬元， 主要原因是：(1)非流動資產減值虧損增加人民幣140.7百萬元；(2)於聯營公司 的投資的減值虧損增加人民幣7.9百萬元；及(3)金融資產減值虧損淨額增加人 民幣119.1百萬元。 主要經營數據 截至十二月三十一日 止年度 增長額╱ 二零二二年 二零二一年 （減少額） ...

Revenue Performance - The company's revenue for the first half of 2022 was RMB 280.1 million, a decrease of 2.0% year-on-year[12]. - Medical service revenue amounted to RMB 276.9 million, down 1.8% compared to the same period last year[12]. - The total revenue for the first half of 2022 was RMB 280.1 million, a decrease of 2.0% compared to RMB 285.8 million in the same period of 2021[25]. - Total revenue for the six months ended June 30, 2022, was RMB 280,104 thousand, a decrease of 2.6% compared to RMB 285,844 thousand for the same period in 2021[114]. - Total revenue for the six months ended June 30, 2022, was not explicitly stated but is implied to have decreased due to the reported losses and cash flow issues[127]. Pediatric Services - Pediatric service revenue increased by 4.3% year-on-year to RMB 230.6 million, accounting for 83.3% of total medical service revenue[16]. - Pediatric outpatient service revenue was RMB 143.4 million, an increase of 8.1%, while inpatient service revenue was RMB 69.5 million, a slight decrease of 0.4%[16]. - Pediatric services generated revenue of RMB 230.6 million, representing 82.3% of medical services revenue, an increase from 77.3% in the previous year[28]. - The contribution of pediatric specialty services to pediatric outpatient and inpatient revenue remained stable at 42.3%[12]. - The company continues to focus on pediatric and obstetric specialty services, as well as online medical services, indicating a strategic emphasis on expanding its service offerings[127]. Financial Losses - The company recorded a net loss of RMB 234.7 million for the six months ended June 30, 2022, primarily due to strict pandemic control measures and increased market competition[16]. - The loss for the six months ended June 30, 2022, was RMB 234.7 million, compared to a loss of RMB 49.1 million in the same period last year[47]. - The company reported a net loss of RMB 234,741 thousand for the six months ended June 30, 2022, compared to a net loss of RMB 49,141 thousand in the previous year[114]. - The company incurred a loss of RMB 605,240,000 for the six months ended June 30, 2022, compared to a loss of RMB 371,592,000 for the same period in 2021[120]. Expenses and Cost Management - The company's gross profit for the six months ended June 30, 2022, was RMB 66.6 million, a decrease of 11.4% year-on-year, with a gross margin dropping from 26.3% to 23.8%[35]. - Sales expenses increased by 17.3% year-on-year to RMB 32.5 million, primarily due to the expansion of the marketing team to recover revenue scale under ongoing pandemic control measures[36]. - Administrative expenses decreased by 7.1% to RMB 64.5 million, compared to RMB 69.4 million in the same period last year, due to enhanced operational management and cost-cutting measures[38]. - Research and development expenses were RMB 4.2 million, down from RMB 5.9 million in the previous year, mainly due to reduced R&D activities[39]. - The company aims to optimize its structure and talent management to strengthen cost control[22]. Asset and Liability Management - Total assets as of June 30, 2022, were RMB 1,016,893 thousand, down from RMB 1,270,896 thousand at the end of 2021, representing a decrease of 20%[112]. - Current liabilities increased to RMB 354,016 thousand from RMB 291,177 thousand, an increase of 21.5%[112]. - The company recorded a significant increase in financial asset impairment losses to RMB 115,352 thousand from RMB 1,035 thousand year-on-year[114]. - Trade receivables increased by 7.9% to RMB 42.5 million, driven by higher receivables from health insurance agencies[51]. - Inventory decreased by 11.4% to RMB 18.7 million from RMB 21.1 million as of December 31, 2021, due to increased stockpiling during peak medical service demand[50]. Shareholder Information - Major shareholders include JoeCare with a 30.8% stake and Victor Gains Limited with an 11.8% stake as of June 30, 2022[77]. - The company has a total of 150,817,051 shares held directly by Jason ZHOU, reflecting his ownership in the issued share capital[81]. - The company has 31,562,713 shares held by 博裕（上海）股權投資管理有限責任公司, representing approximately 6.4% of the company's equity[80]. - 中國人壽再保險有限責任公司 holds 31,444,000 shares, also accounting for about 6.4% of the company's equity[80]. - The employee share plan has resulted in the purchase of 2,073,500 shares, which are held in trust for selected participants[90]. Governance and Compliance - The company has adhered to all applicable corporate governance code provisions as of June 30, 2022, except for the separation of the roles of Chairman and CEO[97]. - The audit committee, consisting of two independent non-executive directors and one non-executive director, has reviewed the interim results for the six months ended June 30, 2022[101]. - The company confirms that there have been no significant changes in the information disclosed in the annual report compared to the current data as of June 30, 2022[102]. - The company has adopted a strict code of conduct for securities trading by directors and employees, with no violations reported as of June 30, 2022[98]. - The company has not disclosed any significant changes in director information since the last annual report[99]. Impairment and Credit Losses - The company recorded an impairment loss on non-current assets of RMB 82.8 million, including RMB 37.3 million for intangible assets and RMB 33.6 million for goodwill[40]. - Financial asset impairment losses amounted to RMB 115.4 million, primarily due to expected credit losses from receivables[43]. - The expected credit loss rate for trade receivables (third-party) is 0.86%, with a total book value of RMB 42,639 thousand and an expected credit loss of RMB 368 thousand[150]. - The expected credit loss rate for trade receivables from individual customers is 90.90%, with a total book value of RMB 2,120 thousand and an expected credit loss of RMB 1,927 thousand[150]. - The total expected credit loss across all categories amounts to RMB 234,055 thousand, with a net loss book value of RMB 129,474 thousand[150]. Future Plans and Strategies - The company aims to enhance its medical service model to meet the refined, professional, and personalized health development needs of new-generation families[11]. - The company plans to enhance customer management systems to improve customer experience and increase membership base[20]. - The company is strengthening market promotion and partnerships with insurance institutions to enhance customer coverage[21]. - The company has adopted restricted share incentive plans to attract and retain key employees[69]. - The company plans to continue monitoring the performance of cash-generating units to assess goodwill impairment[183].

Financial Performance - The company's annual revenue for 2021 showed significant improvement compared to 2020, particularly in pediatric services, driven by the development of multi-specialty clinical services and refined customer operation management [15]. - The company's revenue for the year ended December 31, 2021, was RMB 632.6 million, representing a year-on-year increase of 23.4% [20]. - Medical service revenue reached RMB 621.3 million, up 25.3% year-on-year, with pediatric services contributing RMB 504.1 million, a growth of 37.0% [20]. - The company reported a net loss of RMB 85.3 million, a significant improvement from a net loss of RMB 377.5 million in the previous year [22]. - Adjusted EBITDA for operating medical institutions was RMB 147.6 million, an increase of approximately 21.3% from RMB 121.7 million in the prior year [22]. - The company's loss attributable to owners for the year ended December 31, 2021, was RMB 1,015 million, compared to a loss of RMB 3,714 million for the year ended December 31, 2020 [59]. - The cost of revenue for medical services in 2021 was RMB 425.4 million, up 17.0% year-on-year, primarily due to increased personnel costs and rising expenses for drugs and consumables [44]. - The gross profit for medical services was RMB 195.97 million in 2021, with a gross margin of 31.5%, compared to 26.7% in 2020 [38]. - Income tax expenses for 2021 were RMB 261 million, a decrease of 46.5% year-on-year, mainly due to no deferred tax asset reversals related to cumulative tax losses [57]. - Financial revenue decreased from RMB 33 million in 2020 to RMB 31 million in 2021, primarily due to a reduction in deposit interest [56]. - Financial expenses decreased from RMB 233 million in 2020 to RMB 167 million in 2021, mainly due to a reduction in foreign exchange losses by RMB 52 million and a decrease in interest expenses by RMB 19 million [56]. Service Demand and Growth Opportunities - By the end of 2021, the company had served nearly 360,000 maternal and child families, with 260,000 patient visits during the year, indicating strong demand for its services [16]. - Over 50% of pediatric medical revenue was contributed by pediatric family doctor members and commercial insurance direct payment clients [16]. - The increase in the number of women of advanced maternal age and the demand for high-quality medical services provide significant growth opportunities for the company [15]. - The pediatric business's rapid recovery is attributed to strengthened clinical deployment and service promotion in pediatric surgery and subspecialties [21]. Operational Highlights - Pediatric outpatient service revenue was RMB 302.1 million, reflecting a 49.5% increase, with outpatient visits totaling 204,535, a rise of 36.2% [20]. - Pediatric inpatient service revenue amounted to RMB 162.5 million, increasing by 34.0%, with inpatient visits at 5,834, up 24.7% [20]. - The revenue from outpatient medical services rose by 43.5% year-on-year, while inpatient medical services revenue increased by 11.4% [44]. - The gross profit from hospital consulting services was RMB 3.735 million in 2021, with a gross margin of 80.8%, significantly up from 40.6% in 2020 [45]. Research and Development - Research and development expenses decreased to RMB 10.6 million in 2021 from RMB 14.5 million in the previous year, attributed to reduced R&D activities [51]. - Research and development expenses increased by 20%, totaling $100 million, to support innovation in healthcare technology [108]. Employee and Management Information - The total number of employees increased from 1,352 as of December 31, 2020, to 1,401 as of December 31, 2021, with total employee compensation expenses amounting to RMB 3,225 million in 2021, compared to RMB 2,638 million in 2020 [83]. - The management team has extensive experience in the healthcare industry, with key executives having over 20 years of relevant experience [120][124]. - The company has implemented a restricted share award plan and employee share scheme to attract and retain qualified staff [137]. Corporate Governance and Compliance - The board of directors emphasized the importance of compliance and governance, with independent directors overseeing key decisions [109]. - All independent non-executive directors have confirmed their independence according to the listing rules [167]. - The company has complied with all relevant environmental laws and regulations in China during 2021 [142]. Strategic Initiatives - The company plans to enhance market promotion and insurance partnerships to increase coverage of target customer groups [33]. - The company aims to leverage its technology subsidiary to upgrade operational structures and customer management systems, enhancing customer experience and loyalty [33]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by 2025 [108]. - A strategic acquisition of a smaller competitor was completed, valued at $150 million, aimed at enhancing product offerings [108]. Financial Position and Shareholder Information - As of December 31, 2021, the company had cash and cash equivalents of RMB 2,238 million, down from RMB 2,992 million as of December 31, 2020 [65]. - The company did not recommend a final dividend for the year ended December 31, 2021, consistent with the previous year [84]. - As of December 31, 2021, the company's share premium balance was RMB 2,606.5 million, available for distribution to shareholders [148]. - The company had no borrowings as of December 31, 2021, consistent with the previous year [151]. Supplier and Client Relationships - The top five suppliers accounted for approximately 45.9% of total procurement for the year ended December 31, 2021, down from 55.0% in 2020 [155]. - The company maintained stable relationships with suppliers, ensuring sufficient inventory and bargaining power against price fluctuations [141]. - The company’s major clients contributed less than 5% to total revenue for the year ended December 31, 2021 [155]. Community and Social Responsibility - The company is committed to enhancing its corporate social responsibility initiatives, allocating $10 million for community health programs [108]. - The company is committed to sustainable development by fostering strong relationships with employees, customers, and partners [136].

Revenue and Growth - The company reported revenue of RMB 285.8 million for the first half of 2021, representing a year-on-year increase of 31.9%[20] - Medical service revenue reached RMB 282.0 million, up 34.7% year-on-year, with pediatric services contributing RMB 221.0 million, a 50.4% increase[20] - Revenue from operating medical institutions was RMB 284.2 million, a 34.7% increase from the previous year, with adjusted EBITDA rising approximately 47.9% to RMB 64.8 million[24] - Revenue from medical services reached RMB 282.0 million, a year-on-year increase of 34.7%, accounting for 98.6% of total revenue[37] - Revenue from pediatric services was RMB 220.99 million, accounting for 77.3% of medical service revenue, compared to 67.8% in the previous year[35] - Revenue from obstetric services was RMB 61.01 million, representing a decrease from 28.8% to 21.3% of total medical service revenue[35] - The total revenue for the six months ended June 30, 2021, was RMB 285,844,000, compared to RMB 216,691,000 for the same period in 2020, indicating a year-over-year increase of about 32%[147] Pediatric and Maternal Health Focus - The company noted a strategic focus on pediatric and maternal health services, driven by increasing demand from new generation parents[25] - Pediatric outpatient service revenue was RMB 132.7 million, reflecting a significant growth of 91.8%, with outpatient visits increasing by 83.6% to 91,639[20] - Pediatric inpatient services increased to 2,589 visits, a year-on-year growth of 33.2%, while outpatient services rose to 91,639 visits, up 83.6%[38] - Pediatric outpatient and inpatient service revenue contributions from pediatric surgery and specialized pediatric services increased from 30.6% to 42.7% year-on-year[21] - The proportion of newborns from second and higher-order births increased from 45% in 2016 to 57% in 2019, indicating a growing market for maternal and pediatric services[26] Financial Performance and Losses - The adjusted loss narrowed by 39.2% to RMB 41.7 million compared to RMB 68.6 million in the same period last year[22] - The loss for the six months ended June 30, 2021, was RMB 49.1 million, significantly improved from a loss of RMB 319.3 million in the same period last year[51] - Operating loss decreased to RMB 30,409 thousand from RMB 283,633 thousand year-over-year, reflecting improved operational efficiency[112] - The company reported a net loss of RMB 49,141 thousand for the six months ended June 30, 2021, compared to a net loss of RMB 319,270 thousand in the same period of 2020[112] - Basic and diluted loss per share for the period was RMB (0.11), an improvement from RMB (0.63) in the previous year[115] Expenses and Cost Management - The cost of medical services was RMB 208.5 million, a year-on-year increase of 25.1%, primarily due to business growth and rising personnel costs[38] - Sales expenses for the six months ended June 30, 2021, were RMB 27.7 million, an increase of 38.5% year-on-year, primarily due to the expansion of the marketing team for online business and network expansion[42] - Administrative expenses for the same period were RMB 69.4 million, up 21.5% from RMB 57.1 million in the previous year, mainly due to increased personnel costs following the cancellation of government social security reductions[44] - Research and development expenses amounted to RMB 5.9 million, compared to RMB 5.4 million in the same period last year, related to the development of new online platform technology[45] Assets and Liabilities - The total assets of the company decreased to RMB 1,366,863 thousand from RMB 1,471,045 thousand as of December 31, 2020, representing a decline of approximately 7.1%[107] - The company's non-current assets totaled RMB 879,525 thousand, down from RMB 945,796 thousand, indicating a decrease of about 7%[107] - Current assets decreased to RMB 487,338 thousand from RMB 525,249 thousand, reflecting a decline of approximately 7.2%[107] - The total liabilities as of June 30, 2021, were RMB 638,717 thousand, a decrease from RMB 659,193 thousand at the end of 2020[112] - Non-current liabilities totaled RMB 343,680 thousand, down from RMB 379,687 thousand, indicating a reduction in long-term financial obligations[112] Shareholder Information and Equity - Jason Zhou holds a controlling interest with approximately 44.40% of the company's equity, amounting to 217,556,394 shares[72] - JoeCare holds 150,817,051 shares, representing approximately 30.78% of the company's equity[76] - Victor Gains Limited owns 57,740,181 shares, accounting for approximately 11.8% of the company's equity[76] - Major shareholders include China Life Reinsurance Company and China Reinsurance (Group) Corporation, each holding approximately 6.5% of the company's equity[78] - The board of directors did not recommend the payment of an interim dividend for the six months ended June 30, 2021[69] Operational Adjustments and Future Plans - The company is adjusting operations in response to the ongoing impact of the COVID-19 pandemic on newly opened clinics[24] - The company aims to leverage national policies promoting children's health management to enhance public awareness and service demand[25] - The company plans to enhance brand building and market promotion to increase coverage of target customer groups[30] - The company aims to optimize its business and organizational structure while implementing employee incentive plans[30] - The company is focusing on pediatric subspecialty development and enhancing operational capabilities through technology integration[30] Cash Flow and Investments - Operating cash flow for the six months ended June 30, 2021, was RMB 26,624 thousand, compared to RMB 5,536 thousand in 2020, representing a significant increase[123] - Net cash inflow from operating activities was RMB 8,188 thousand, a turnaround from a net outflow of RMB (8,077) thousand in the same period last year[123] - Net cash outflow from investing activities was RMB (9,778) thousand, compared to a net inflow of RMB 20,609 thousand in 2020, indicating a shift in investment strategy[123] - The remaining amount for new hospitals and clinics is expected to be fully utilized by the end of 2023[92] - The remaining amount for investment in surgical centers and medical service technology is also expected to be fully utilized by the end of 2023[92] Compliance and Governance - The company maintained compliance with the corporate governance code, except for the separation of the roles of Chairman and CEO, which are held by the same individual, Jason Zhou[95] - The audit committee, consisting of independent non-executive directors, reviewed the interim results and confirmed compliance with relevant accounting standards[99] - The company has adopted a strict code of conduct for securities trading by directors and employees, with no reported violations during the review period[96]

新世紀醫療控股有限公 New Century Healthcare Holding Co. Limited New Century Healthcare Holding Co. Limited 新世紀醫療控股有限公司 司 (Incorporated in the Cayman Islands with limited liability) Stock Code: 1518 ANNUAL REPORT 2020 年度報告 2020 ANNUAL REPORT 股份代號 Stock Code: 1518 New Century Healthcare Holding Co. Limited 新世紀醫療控股有限公司 （於開曼群島註冊成立的有限公司） 股份代號：1518 年度報告 2020 En NH H-++++ b nF TT FET ANTING ITARSHING / Property of respondation RTHER HOLDER 60 目錄 公司資料 2 主席報告 4 管理層討論與分析 6 董事及高級管理層 17 董事會報告 25 企業管治報告 47 環境、社會及管治報告 59 獨立核數師報告 6 ...

Financial Performance - The company's revenue for the first half of 2020 was RMB 216.7 million, a decrease of 36.7% year-on-year, marking the first negative growth since its listing in January 2017[9]. - Medical service revenue was RMB 209.3 million, down 34.4% year-on-year, impacted by the COVID-19 pandemic[9]. - The company reported a net loss of RMB 319.3 million for the first half of 2020, with an adjusted net profit of RMB 9.8 million and adjusted EBITDA of RMB 40.1 million[9]. - Total revenue for the six months ended June 30, 2020, was RMB 216,691 thousand, a decrease of 36.7% compared to RMB 342,488 thousand in the same period of 2019[103]. - Gross profit for the period was RMB 42,331 thousand, down 64.5% from RMB 119,088 thousand year-on-year[103]. - The company reported a net loss of RMB 319,270 thousand for the six months ended June 30, 2020, compared to a profit of RMB 4,006 thousand in the same period of 2019[103]. - The company reported a net loss attributable to shareholders of RMB 308,036,000 for the six months ended June 30, 2020, compared to a net loss of RMB 9,392,000 for the same period in 2019, resulting in a basic loss per share of RMB (0.63) compared to RMB (0.02) in 2019[200]. - Total expenses for the six months ended June 30, 2020, were RMB 256,923,000, a decrease of 17.6% from RMB 311,815,000 in 2019[192]. Revenue Breakdown - Pediatric business revenue was RMB 146.9 million, a decline of 42.5% year-on-year, with outpatient visits down 56.1%[12]. - The total revenue for the pediatric services segment was RMB 146,943 thousand, with a cost of revenue of RMB 114,892 thousand, resulting in a segment performance loss before tax of RMB (87,134) thousand[145]. - Medical service revenue for the six months ended June 30, 2020, was RMB 209.3 million, a decrease of 34.4% year-on-year, accounting for 96.6% of total revenue[23]. - Online medical services contributed to 10.1% of total consultations, with a total of 79,510 visits, including 8,017 online consultations[10]. Operational Impact - The pediatric outpatient visit volume has recovered to 90% of the same month last year as of August 2020[12]. - Inpatient services for pediatrics saw a decline of 50.3% with 1,944 visits, while outpatient services decreased by 56.1% with 49,903 visits, primarily due to the impact of COVID-19[24]. - The company expects future operations to be further impacted by ongoing COVID-19 pandemic measures, which have already significantly affected performance[164]. Cost Management - The cost of medical services for the six months ended June 30, 2020, was RMB 166.7 million, a decrease of 21.4% year-on-year, attributed to personnel structure adjustments and reduced operational costs[26]. - The average outpatient spending for pediatric services increased by 16.3% year-on-year to RMB 1,388[12]. - The average inpatient expenditure for pediatrics increased to RMB 27,764, up from RMB 24,561 in the previous year[21]. - The average outpatient expenditure for pediatrics rose to RMB 1,265, compared to RMB 1,140 in the previous year[21]. Financial Position - Cash and cash equivalents as of June 30, 2020, were RMB 308.1 million, down from RMB 349.1 million as of December 31, 2019[45]. - Total assets decreased to RMB 1,519,676 thousand as of June 30, 2020, from RMB 1,876,668 thousand as of December 31, 2019, representing a decline of 19.1%[101]. - The company’s equity attributable to owners decreased to RMB 904,363 thousand from RMB 1,210,805 thousand at the end of 2019, a decline of 25.3%[98]. - The company recorded an impairment loss on intangible assets of RMB 251,461 thousand during the period[103]. Strategic Initiatives - The company plans to enhance its online and offline medical service integration and upgrade offline service scenarios through data[17]. - The company aims to optimize its management structure and explore strategic collaborations across different industries[17]. - The company has integrated IT development and marketing resources to enhance operational efficiency and service delivery[8]. Employee and Governance - The total employee compensation for the six months ended June 30, 2020, was RMB 125.9 million, a decrease from RMB 149.9 million for the same period in 2019[58]. - As of June 30, 2020, the company had 1,350 employees, an increase from 1,307 employees as of June 30, 2019[58]. - The company has adopted restricted share incentive plans to attract and retain key employees[58]. - The company has adhered to the Corporate Governance Code, except for the separation of the roles of Chairman and CEO, which are held by Jason Zhou[85]. Legal and Compliance - The company is involved in ongoing legal proceedings with Serenium Inc., with a favorable arbitration ruling received on August 4, 2020[60]. - The audit committee reviewed the interim results for the six months ending June 30, 2020, and confirmed compliance with relevant accounting standards[89]. Market Outlook - The pediatric medical market is projected to reach RMB 224 billion by 2022, with private medical institutions accounting for 6.1%[14]. - The government continues to support the development of online medical services as part of its national strategy, promoting the integration of internet technology in healthcare[16].